MG
APGE icon

Michael Gelband’s Apogee Therapeutics APGE Stock Holding History

Michael Gelband’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
+87,500
New +$7.88M 0.07% 257

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Michael Gelband's APGE Position: Q2 2026 in Review

Michael Gelband opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 348 shares worth $46.2K. The stake represents ﹤0.01% of the portfolio and ranks #1489 among its holdings. This is a return to the name: Michael Gelband previously reported a position in APGE as recently as Q3 2025.

Michael Gelband first reported a position in APGE in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.49M in Q3 2025. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Michael Gelband held 348 shares of Apogee Therapeutics worth $46.2K as of Q2 2026.
  • Apogee Therapeutics was a new Michael Gelband position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1489 holding.
  • Michael Gelband first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Michael Gelband's Apogee Therapeutics position peaked at $1.49M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.